# Metabolomic Data Analysis with MetaboAnalyst 6.0

Name: guest12043074286052650607

January 13, 2025

### 1 Background

MSEA or Metabolite Set Enrichment Analysis is a way to identify biologically meaningful patterns that are significantly enriched in quantitative metabolomic data. In conventional approaches, metabolites are evaluated individually for their significance under conditions of study. Those compounds that have passed certain significance level are then combined to see if any meaningful patterns can be discerned. In contrast, MSEA directly investigates if a set of functionally related metabolites without the need to preselect compounds based on some arbitrary cut-off threshold. It has the potential to identify subtle but consistent changes among a group of related compounds, which may go undetected with the conventional approaches.

Essentially, MSEA is a metabolomic version of the popular GSEA (Gene Set Enrichment Analysis) software with its own collection of metabolite set libraries as well as an implementation of user-friendly web-interfaces. GSEA is widely used in genomics data analysis and has proven to be a powerful alternative to conventional approaches. For more information, please refer to the original paper by Subramanian A, and a nice review paper by Nam D, Kim SY. <sup>1</sup>. <sup>2</sup>

#### 2 MSEA Overview

Metabolite set enrichment analysis consists of four steps - data input, data processing, data analysis, and results download. Different analysis procedures are performed based on different input types. In addition, users can also browse and search the metabolite set libraries as well as upload their self-defined metabolite sets for enrichment analysis. Users can also perform metabolite name mapping between a variety of compound names, synonyms, and major database identifiers.

### 3 Data Input

There are three enrichment analysis algorithms offered by MSEA. Accordingly, three different types of data inputs are required by these three approaches:

- A list of important compound names entered as a one column data (Over Representation Analysis (ORA));
- A single measured biofluid (urine, blood, CSF) sample- entered as tab separated two-column data with the first column for compound name, and the second for concentration values (Single Sample Profiling (SSP));

<sup>&</sup>lt;sup>1</sup>Subramanian Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles., Proc Natl Acad Sci USA. 2005 102(43): 15545-50

<sup>&</sup>lt;sup>2</sup>Nam D, Kim SY. Gene-set approach for expression pattern analysis, Briefings in Bioinformatics. 2008 9(3): 189-197.

• A compound concentration table - entered as a comma separated (.csv) file with the each sample per row and each metabolite concentration per column. The first column is sample names and the second column for sample phenotype labels (Quantitative Enrichment Analysis (QEA))

You selected Over Representation Analysis (ORA) which requires a list of compound names as input.

#### 4 Data Process

The first step is to standardize the compound labels. It is an essential step since the compound labels will be subsequently compared with compounds contained in the metabolite set library. MSEA has a built-in tool to convert between compound common names, synonyms, identifiers used in HMDB ID, PubChem, ChEBI, BiGG, METLIN, KEGG, or Reactome. **Table 1** shows the conversion results. Note: 1 indicates exact match, 2 indicates approximate match, and  $\theta$  indicates no match. A text file contain the result can be found the downloaded file name map.csv

Table 1: Result from Comp

2 C00958         Phosphory Icholine         HMBB0001143         1885         C0075         CNI+(C)(C)CCOP(O)(G)(G)OP(O)(		Query	Match	HMDB	PubChem	KEGG	SMILES
3 C00307   Ciricoline   HMDB0000288   6030   C0015   C0011   C016@H  C0Ce@H  C0CeO  C0CH  C0Ce@H  C0CeO  C0CH  C0CeO  C0CeO  C0CH  C0CeO  C0Ce		C00670	Glycerophosphocholine	HMDB0000086	657272	C00670	C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)
4 C00105         Uridine 5 'monophosphate         HMDB0000298 (6031 C00105 O) C C							
5 C00015         Uridine 5 - diphosphate         HMDB0000295         6031         C00012         Occur2NCN(Ce@H](o)[c@@H](cOP(O)           6 C00020         Adenosine monophosphate         HMDB00003337         6835         C00027         NC1=C2N-CN(Ce@H](3C)[c@H](CSC)(Ce@H](CSC)(Ce]           8 C00028         C0028         NC20H](CC1=CCC)(C](C)(C)(C)(C)(C)(C)(C)           9 C19463         L. Tyrosine         HMDB0003181         16720         C19463         NC1=CC=CC2=C1C=CC=C2N           10 C20381         Blotin sulfone         HMDB00004818         16720         C19463         NC1=CC=CC2=C1C=CC=C2N           11 C00319         Sphingssine         HMDB0000252         5280335         C00319         CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	3			HMDB0001413	13805	C00307	C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC
6 C 00020         Adenosine monophosphate         HMDB00000345         6835         C00020         NC1=C2N=CN\[C@H]SO\[C@H]SO\[C@H]GO\[C]CSO\[C]CBH][COC]C=0]           8 C 00082         L-Tyrosine         HMDB0000318         6535         C00020         NC1=C2N=CN\[C@H]SO\[C@H]GO\[C]CSO\[C]CC]C=C]           9 C 19483         L-Tyrosine         HMDB0000188         6557         C00082         NC1=C2-CC2C=C1=CCCC2N           10 C 20387         Blotin sulfone         HMDB0000818         21252323         C0337         H[[C@H]COC]CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	4		Uridine 5'-monophosphate	$\mathrm{HMDB0000288}$	6030	C00105	O[C@H]1[C@@H](O)[C@@H](O[C@@H]1CO
7 C00127         Condigate glutathione         HMDB00001337         63.559         C00128         N[C@@H](CCC=C]=O)P(C=C)P(O]=C](O]=O           9 C19463         1.5-Naphthalenediamine         HMDB0004121         16720         C19463         NC1=CC=CC2=C1C=CC=C2N           10 C20337         Biotin sulfone         HMDB000418         21252323         C03387         H∏(EB](ESC=CO)(-O)(-O)(-O)(-O)(-O)(-O)(-O)(-O)(-O)(-	5	C00015	Uridine 5'-diphosphate	${ m HMDB0000295}$	6031	C00015	O[C@H]1[C@@H](O)[C@@H](O[C@@H]1CO
8 C00082 L. Tyrosine	6	C00020	Adenosine monophosphate	HMDB0000045	6083	C00020	NC1=C2N=CN([C@@H]3O[C@H](COP(O)(
9 C19463	7	C00127	Oxidized glutathione	HMDB0003337	65359	C00127	N[C@@H](CCC(=O)N[C@@H](CSSC[C@H])
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	8	C00082		HMDB0000158	6057	C00082	N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	9	C19463	1,5-Naphthalenediamine	HMDB0244231	16720	C19463	NC1=CC=CC2=C1C=CC=C2N
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	10	C20387		HMDB0004818	21252323	C20387	[H][C@]12CS(=O)(=O)[C@@H](CCCCC(O)
132   Co2999   Palmitoylcarnitine	11	C00319	Sphingosine	${ m HMDB0000252}$	5280335	C00319	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	12	C04230	CE(22.5(7Z,10Z,13Z,16Z,19Z))	HMDB0010375	24779458	C04230	$CC \ C = C/C \ C \ C = C/C \ C \ C \ C \ C \ C \ C \ C \ C \ C$
15	13	C02990	Palmitoylcarnitine	${\rm HMDB0000222}$	11953816	C02990	CCCCCCCCCCCCCC(=O)O[C@H](CC(
15	14	C11339	Antimycin A	HMDB0248488	12550	C11339	CCCCCC1C(OC(=O)CC(C)C)C(C)OC(=
17	15	C02301	O-Acylcarnitine		5355	C02301	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	16	C21484	LysoPE(18:0/0:0)	HMDB0011130	9547068	C21484	[H][C@@](O)(COC(=O)CCCCCCCCCCCC
19	17	C00199	D-Ribulose 5-phosphate	HMDB0000618	439184	C00199	OCC(=O)[C@H](O)[C@H](O)COP(O)(O)=0
C03546	18	C01657	N-Acetyl-L-tyrosine	HMDB0000866	68310	C01657	CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	19	C00093	Glycerol 3-phosphate	HMDB0000126	439162	C00093	OC[C@@H](O)COP(O)(O)=O
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	20	C03546	D-myo-Inositol 4-phosphate	HMDB0001313	440043	C03546	O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	21	C05382	D-Sedoheptulose 7-phosphate	HMDB0001068	92042786	C05382	OC[C@]1(O)O[C@H](COP(O)(O)=O)[C@@]
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$^{22}$	C00052	Uridine diphosphategalactose	${\rm HMDB0000302}$	18068	C00052	OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	23	C00167	Uridine diphosphate glucuronic acid	HMDB0000935	17473	C00167	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$^{24}$	C00364	5-Thymidylic acid	${ m HMDB0001227}$	9700	C00364	CC1=CN([C@H]2C[C@H](O)[C@@H](COP(
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$^{25}$	C00299	Uridine	${\rm HMDB0000296}$	6029	C00299	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$^{26}$	C03794		${ m HMDB0000536}$	447145	C03794	O[C@@H]1[C@@H](COP(O)(O)=O)O[C@H]
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$^{27}$	C00005	NADPH	${\rm HMDB0000221}$	5884	C00005	NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	28			${ m HMDB0000929}$			N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	29	C03672	Hydroxyphenyllactic acid	${ m HMDB0000755}$	9378	C03672	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	30	C00463	Indole	HMDB0000738	798		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	31	C07471	Methacholine	${ m HMDB0015654}$	1993	C07471	
34         C00157         Phosphatidylcholine         C00157           35         C00550         2beta-Hydroxytestosterone         HMDB0012654         53481791         C00550         C[C@]12CCC3C(CCC4=CC(=O)[C@@H](CC(=O)]C@@H](CC(=O)]C@@H](CC(=O)]C@@H](CC(=O)]C@@H](CC(=O)]C@@H](CC(=O)]C@@H](CC(=O)]C@@H](CC(=O)]C@@H](CC(=O)]C@H](CC(=O)]C(=O)C(=O)]C(=O)C(=O)C(=O)]C(=O)C(=O)C(=O)C(=O)C(=O)C(=O)C(=O)C(=O)	32	C00360		${ m HMDB0000905}$	12599	C00360	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	33	C00350		HMDB0008834	52924120	C00350	[H][C@@](COC(=O)CCCCCCCCCCCC)(GCCCCCCCCCCCCCCCCCCCCCCC
36         C00380         Cytosine         HMDB0000630         597         C00380         NC1=CC=NC(=O)N1           37         C02862         Butyrylcarnitine         HMDB0002013         213144         C02862         CCCC(=O)O[C@H](CC([O-])=O)C[N+](C           38         C00029         Uridine diphosphate glucose         HMDB000286         8629         C00029         CC[C@H]1O[C@H](OP(O)(=O)OP(O)(CO)           40         C02205         Phosphocreatine         HMDB001510         6049         C00284         CC(=O)CN(CCN(CC(O)=O)CC(O)=O)C           41         C00570         CDP-ethanolamine         HMDB0001564         123727         C00570         NCCOP(O)(=O)OP(							
37         C02862         Butyrylcarnitine         HMDB0002013         213144         C02862         CCCC(=O)O[C@H](CC([O-])=O)C[N+](C           38         C00029         Uridine diphosphate glucose         HMDB000286         8629         C00029         OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)           40         C02305         Phosphocreatine         HMDB001511         587         C02305         CN(CC(O)=O)C(=N)NP(O)(O)=O           41         C00570         CDP-ethanolamine         HMDB0001564         123727         C00570         NCCOP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]1O[           42         C14550         4-Nonylphenol         HMDB0038982         1752         C14550         CCCCCCCCCC1=CC=C(O)C=C1           43         C00946         Adenosine 2'-phosphate         HMDB0011617         53481006         C00946         NC1=NC=NC2=C1N=CN2C1O[C@H](CC           44         C05282         gamma-Glutamylglutamic acid         HMDB0011737         92865         C05282         N[C@GH](CCC(=O)N[C@GH](CCC(=O)N[C@GH](O)[C@H	35	C00550	2bet a-Hydroxytestosterone	${ m HMDB0012654}$	53481791	C00550	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	36	C00380		HMDB0000630	597	C00380	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$				HMDB0002013			$CCCC(=O)O[\hat{C}@H](CC([O-])=O)C[N+](C)$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	38	C00029	Uridine diphosphate glucose	${ m HMDB0000286}$	8629	C00029	OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	39	C00284		${ m HMDB0015109}$	6049	C00284	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC
42         C14550         4-Nonylphenol         HMDB0038982         1752         C14550         CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	40						
43         C00946         Adenosine 2'-phosphate         HMDB0011617         53481006         C00946         NC1=NC=NC2=C1N=CN2C1O[C@H](CC         C0EH](CC         44         C05282         N[C@@H](CCC(=O)N[C@@H](CC(=O)N[C@@H](CC(=O))]         COEH](CCC(=O)N[C@@H](CC(=O)N[C@@H](O)[C@	41	C00570		${ m HMDB0001564}$	123727	C00570	NCCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C
44 C05282 gamma-Glutamylglutamic acid HMDB0011737 92865 C05282 N[C@@H](CCC(=O)N[C@@H](CCC(O)=C + + + + + + + + + + + + + + + + + + +							
$45  \text{C00043}  \text{Uridine diphosphate-N-acetylglucosamine}  \text{HMDB0000290}  445675 \qquad \text{C00043}  CC(=O)NC@@H](O)[C@H](O$	43	C00946	Adenosine 2'-phosphate	${ m HMDB0011617}$	53481006	C00946	NC1=NC=NC2=C1N=CN2C1O[C@H](CO)
	44			HMDB0011737	92865		N[C@@H](CCC(=O)N[C@@H](CCC(O)=O)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	45		Uridine diphosphate-N-acetylglucosamine	${\rm HMDB0000290}$	445675	C00043	CC(=O)NC@@H]1C@@H](O)C@H)(O)C@H
	$^{46}$	C00103	Glucose 1-phosphate	${\rm HMDB0001586}$	65533	C00103	OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)

The second step is to check concentration values. For SSP analysis, the concentration must be measured in umol for blood and CSF samples. The urinary concentrations must be first converted to  $umol/mmol\_creatinine$  in order to compare with reported concentrations in literature. No missing or negative values are allowed in SSP analysis. The concentration data for QEA analysis is more flexible. Users can upload either the original concentration data or normalized data. Missing or negative values are allowed (coded as NA) for QEA.

### 5 Selection of Metabolite Set Library

Before proceeding to enrichment analysis, a metabolite set library has to be chosen. There are seven built-in libraries offered by MSEA:

- Metabolic pathway associated metabolite sets (currently contains 99 entries);
- Disease associated metabolite sets (reported in blood) (currently contains 344 entries);
- Disease associated metabolite sets (reported in urine) (currently contains 384 entries)
- Disease associated metabolite sets (reported in CSF) (currently contains 166 entries)
- Metabolite sets associated with SNPs (currently contains 4598 entries)
- Predicted metabolite sets based on computational enzyme knockout model (currently contains 912 entries)
- Metabolite sets based on locations (currently contains 73 entries)
- Drug pathway associated metabolite sets (currently contains 461 entries)

In addition, MSEA also allows user-defined metabolite sets to be uploaded to perform enrichment analysis on arbitrary groups of compounds which researchers want to test. The metabolite set library is simply a two-column comma separated text file with the first column for metabolite set names and the second column for its compound names (must use HMDB compound name) separated by "; ". Please note, the built-in libraries are mainly from human studies. The functional grouping of metabolites may not be valid. Therefore, for data from subjects other than human being, users are suggested to upload their self-defined metabolite set libraries for enrichment analysis.

## 6 Enrichment Analysis

Over Representation Analysis (ORA) is performed when a list of compound names is provided. The list of compound list can be obtained through conventional feature selection methods, or from a clustering algorithm, or from the compounds with abnormal concentrations detected in SSP, to investigate if some biologically meaningful patterns can be identified.

ORA was implemented using the *hypergeometric test* to evaluate whether a particular metabolite set is represented more than expected by chance within the given compound list. One-tailed p values are provided after adjusting for multiple testing. **Figure 2** below summarizes the result.

#### **Metabolite Sets Enrichment Overview**




Figure 1: Summary Plot for Over Representation Analysis (ORA)

Table 2: Result from Over Representation Analysis

	total	expected	hits	Raw p	Holm p	FDR
Glycerophospholipid metabolism		1.42	5	3.03E-03	2.43E-01	2.43E-01
	6		_			
Pyrimidine metabolism	5	1.18	4	1.16E-02	9.15E-01	3.35E-01
Pentose and glucuronate interconversions	3	0.71	3	1.26E-02	9.80E-01	3.35E-01
Amino sugar and nucleotide sugar	4	0.95	3	4.19E-02	1.00E+00	7.35E-01
$\operatorname{metabolism}$						
Galactose metabolism	2	0.47	2	$5.51\mathrm{E} ext{-}02$	1.00E+00	7.35E-01
Ascorbate and aldarate metabolism	2	0.47	2	5.51E-02	1.00E+00	7.35E-01
Glutathione metabolism	3	0.71	2	1.40E-01	1.00E + 00	1.00E + 00
Fatty acid degradation	1	0.24	1	$2.37\mathrm{E}\text{-}01$	1.00E + 00	1.00E + 00
Ubiquinone and other terpenoid-quinone	1	0.24	1	$2.37\mathrm{E}\text{-}01$	1.00E + 00	1.00E + 00
biosynthesis						
Alanine, aspartate and glutamate	1	0.24	1	$2.37\mathrm{E}\text{-}01$	1.00E + 00	1.00E + 00
metabolism						
Tyrosine metabolism	1	0.24	1	2.37E-01	1.00E + 00	1.00E + 00
Phenylalanine metabolism	1	0.24	1	2.37E-01	1.00E + 00	1.00E + 00
Phenylalanine, tyrosine and tryptophan	1	0.24	1	2.37E-01	1.00E+00	1.00E + 00
biosynthesis					, i	, i
Starch and sucrose metabolism	1	0.24	1	2.37E-01	1.00E + 00	$1.00 \mathrm{E} \! + \! 00$
Glycerolipid metabolism	1	0.24	1	2.37E-01	1.00E + 00	1.00E + 00
Inositol phosphate metabolism	1	0.24	1	2.37E-01	1.00E+00	1.00E + 00
Ether lipid metabolism	1	0.24	1	2.37E-01	1.00E + 00	1.00E + 00
Pentose phosphate pathway	2	0.47	1	4.19E-01	1.00E + 00	1.00E + 00
Tryptophan metabolism	2	0.47	1	4.19E-01	1.00E + 00	1.00E + 00
Sphingolipid metabolism	2	0.47	1	4.19E-01	1.00E + 00	1.00E + 00
Arginine and proline metabolism	3	0.71	1	5.58E-01	1.00E + 00	$1.00 \mathrm{E} \! + \! 00$
Purine metabolism	12	2.84	3	$5.74  ext{E-}01$	1.00E+00	$1.00\mathrm{E}\!+\!00$

## 7 Appendix: R Command History

```
[1] "mSet<-InitDataObjects(\"conc\", \"msetora\", FALSE)"
[2] "cmpd.vec<-c(\"C00670\",\"C00588\",\"C00307\",\"C00105\",\"C00015\",\"C00020\",\"C00127\",\"C00
[3] "mSet<-Setup.MapData(mSet, cmpd.vec);"
[4] "mSet<-CrossReferencing(mSet, \"kegg\");"
[5] "mSet<-CreateMappingResultTable(mSet)"
[6] "mSet<-Setup.HMDBReferenceMetabolome(mSet, \"AmA.txt\");"
[7] "mSet<-SetMetabolomeFilter(mSet, T);"
[8] "mSet<-SetCurrentMsetLib(mSet, \"kegg_pathway\", 2);"
[9] "mSet<-CalculateHyperScore(mSet)"
[10] "mSet<-PlotORA(mSet, \"ora_0_\", \"net\", \"png\", 72, width=NA)"
[11] "mSet<-PlotEnrichDotPlot(mSet, \"ora\", \"ora_dot_0_\", \"png\", 72, width=NA)"
[12] "mSet<-CalculateHyperScore(mSet)"
[13] "mSet<-PlotORA(mSet, \"ora_1_\", \"net\", \"png\", 72, width=NA)"
[14] "mSet<-PlotEnrichDotPlot(mSet, \"ora\", \"png\", 72, width=NA)"
[15] "mSet<-SaveTransformedData(mSet)"
[16] "mSet<-PreparePDFReport(mSet, \"guest12043074286052650607\")\n"</pre>
```

The report was generated on Mon Jan 13 05:39:43 2025 with R version 4.3.2 (2023-10-31), OS system: Linux.